


Patient Information		PROVEN DIAGNOSTICS
Name: TESTING, PATIENT #3 DOB (AGE) Sex: 3/15/1936 (73) M MRN (Client MRN): 309092008		
Billing #: 309092008 Order #:		
Client Information	Specimen Information	
Location: D3B Copy To: Outside Client.:	Collected Date: 7/23/2009 Accession Date: 7/23/2009 Reported Date: 7/24/2009 Submitting: - Dr Testing	Accession #: S09-356 Client Case #: Report Type: Final Report

SURGICAL PATHOLOGY DIAGNOSIS

Electronically Signed Out: Steven C. Meschter, M.D. - GMC Lab



Prostate Biopsy

Part	Location	Core (cm)	Diagnosis	Gleason	PN inv	% PCA
A	Left lateral base	1.8	Benign			
B	Left base	1.6	Benign			
C	Midline base	0.8	Benign			
D	Right base	2.0	Benign			
E	Right lateral base	2.2	Prostatic Adenocarcinoma	3+4=7	No	10%
F	Left lateral mid	2.0	Benign			
G	Left mid	2.0	Benign			
H	Right mid	1.5	Benign			
I	Right lateral mid	2.0	Prostatic Adenocarcinoma	3+4=7	No	5%
J	Left lateral apex	1.2	Prostatic Adenocarcinoma	3+3=6	No	40%
K	Left apex	1.6	Benign			
L	Right apex	2.5	Benign			
M	Right lateral apex	1.9	HGPIN			

*PCA = Prostate Carcinoma

*Core = total length of cores submitted

*PN inv = Perineural Invasion

*HGPIN = High grade prostatic intraepithelial neoplasia

Clinical History

Elevated PSA 4.0

Microscopic Findings

Immunohistochemistry Results

Part	Basal Cells p63/CK903	Cytoplasmic p504s
E	Absent	Positive
M	Present	Positive

CPT Code(s): A: 88305; B: 88305; C: 88305; D: 88305; E: 88305,88342IMMUNOP(3); F: 88305; G: 88305; H: 88305; I: 88305; J: 88305,88342IMMUNOP(3); K: 88305; L: 88305; M: 88305

Photographic images and diagrams represent key findings in this case; they are not intended to replace a complete review of the final diagnostic report.

The following statement applies to Flow Cytometry, Immunohistochemistry, Molecular Genetics, Immunofluorescence, and In situ Hybridization Assays: This test was developed and its performance characteristics determined by Geisinger Medical Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for reasearch.

TESTING, PATIENT #3

MRN: 309092008

S09-356

Page 1 of 1

Conrad Schuerch, MD, Medical Director, Geisinger Medical Center Laboratory, 100 N. Academy Ave, Danville, Pa. 17822-0131, 800-695-6491
 Geisinger Wyoming Valley Medical Center Laboratory, 1000 E. Mtn. Dr. Wilkes-Barre, Pa. 18711